Company news

Sarepta Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments

October 31, 2023

Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy

October 29, 2023

Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results

October 24, 2023

Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year

September 6, 2023

Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 4, 2023

Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test

August 29, 2023

Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments

August 1, 2023

Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results

July 25, 2023

Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million

July 4, 2023

Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit

July 2, 2023

Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

June 21, 2023

Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001

May 23, 2023

Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

May 11, 2023

Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments

May 1, 2023

Sarepta Therapeutics to Announce First Quarter 2023 Financial Results

April 24, 2023

Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023

April 9, 2023

Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001

March 15, 2023

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

February 27, 2023

Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program

February 27, 2023

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results

February 20, 2023

Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

February 16, 2023

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues

January 8, 2023

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

January 4, 2023

Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

November 27, 2022

Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference

November 22, 2022

Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments

November 1, 2022

Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results

October 25, 2022

Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022

October 6, 2022

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

September 28, 2022

Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027

September 13, 2022

Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027

September 11, 2022

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year

September 6, 2022

Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

September 5, 2022

Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases

August 7, 2022

Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments

August 1, 2022

Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy

July 28, 2022

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022

July 25, 2022

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies

July 5, 2022

Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8: 30am ET

July 4, 2022

Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

June 22, 2022

Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

June 1, 2022

Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors

June 1, 2022

Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

May 3, 2022

Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments

May 3, 2022

Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022

April 26, 2022

Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program

March 7, 2022

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments

February 28, 2022

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022

February 21, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.